Fig. 3.

KLEXJ extract promotes ALP activity and BMP-2 expression through the Akt pathway. (A) Osteoblasts were pretreated with an Akt inhibitor (10 μM) for 30 min or transfected with Akt siRNA for 24 h, followed by stimulation with KLEXJ for 48 h. ALP activity was examined using a commercial ALP assay kit. (B&C) Osteoblasts were pretreated with an Akt inhibitor (10 μM) for 30 min or transfected with Akt siRNA for 24 h, followed by stimulation with KLEXJ for 24 h. BMP-2 expression was examined by qPCR and Western blot analysis. (D) Osteoblasts were incubated with KLEXJ for indicated time intervals and Akt phosphorylation was examined by Western blot analysis. Results are expressed as mean ± S.E.M.*, p < 0.05 compared with control. #, p < 0.05 compared with KLEXJ-treated group.